Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CNR2 | P34972 | 5/20 | 0.65 |
| ▸ | PDE5A | O76074 | 4/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748630 | 1.00 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL31589469 | 1.00 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL1748594 | 1.00 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| Hydrochloric Acid SCHEMBL1749138 | 0.99 | CNR1 (0.64) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL2015856 | 0.94 | CNR1 (0.59) | CNR1CNR2PDE5ANR3C2PRKCZ | |
| SCHEMBL2021231 | 0.94 | CNR1 (0.59) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL14395009 | 0.93 | CNR1 (0.58) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL2017880 | 0.93 | CNR1 (0.58) | CNR1CNR2PDE5ANR3C2 | |
| SCHEMBL2018962 | 0.93 | CNR1 (0.58) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL14621870 | 0.93 | CNR1 (0.58) | CNR1CNR2PDE5ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1946778-A1 | Active substance combination for the treatment of diabetes | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1749526-A1 | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-07 | — | — | EP | claimed |
| EP-1749527-A1 | Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-07 | — | — | EP | claimed |
| WO-2007009702-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, HAVING PREDETERMINED STEREOCHEMISTRY, FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009704-A2 | USE OF SUBSTITUTED PYRAZOLINE COMPOUNDS FOR THE TREATMENT OF FOOD DISORDERS, INCLUDING OBESITY OR METABOLIC SYNDROME IN PATIENTS WITH DEVELOPED DIABETES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009683-A2 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED PYRAZOLINE COMPOUNDS | LABORATORIOS DEL DR.ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009707-A2 | USE OF SUBSTITUTED PYRAZOLINE COMPOUNDS FOR THE TREATMENT OF COAGULATION RELATED DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | US | claimed |
| WO-2007009703-A2 | NEW FORMULATIONS OF SUBSTITUTED PYRAZOLINE COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743639-A1 | Use of substituted pyrazoline compounds for the treatment of coagulation related diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743889-A1 | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1910299-B1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-7968582-B2 | 5(S)-substituted pyrazoline compounds, their preparation and use as medicaments | LABOROTORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-28 | — | — | US | disclosed |
| EP-1743638-A1 | Pharmaceutical formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743639-A1 | Use of substituted pyrazoline compounds for the treatment of coagulation related diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | PIR, SYMPK, P2RX5 | CNR1 990/4885CNR2 748/4885PDE5A 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.